Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.

Literature DB >> 28927986

Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.

Steven A Greenberg¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28927986 PMCID： PMC5628928 DOI： 10.1016/j.ymthe.2017.09.002

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

14 in total

1. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

Authors: C Lindberg; E Trysberg; A Tarkowski; A Oldfors
Journal: Neurology Date: 2003-07-22 Impact factor: 9.910

2. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles.

Authors: Shelly Pranić; Ana Marušić
Journal: J Clin Epidemiol Date: 2015-07-29 Impact factor: 6.437

3. Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet.

Authors: Sanaa Al-Marzouki; Ian Roberts; Stephen Evans; Tom Marshall
Journal: Lancet Date: 2008-07-19 Impact factor: 79.321

4. Comparison of registered and published primary outcomes in randomized controlled trials.

Authors: Sylvain Mathieu; Isabelle Boutron; David Moher; Douglas G Altman; Philippe Ravaud
Journal: JAMA Date: 2009-09-02 Impact factor: 56.272

5. Clinical Trials Registration and Results Information Submission. Final rule.

Authors:
Journal: Fed Regist Date: 2016-09-21

6. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors: Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal: Mol Ther Date: 2017-03-06 Impact factor: 11.454

7. Treatment of sporadic inclusion body myositis with bimagrumab.

Authors: Anthony A Amato; Kumaraswamy Sivakumar; Namita Goyal; William S David; Mohammad Salajegheh; Jens Praestgaard; Estelle Lach-Trifilieff; Anne-Ulrike Trendelenburg; Didier Laurent; David J Glass; Ronenn Roubenoff; Brian S Tseng; Steven A Greenberg
Journal: Neurology Date: 2014-11-07 Impact factor: 9.910

8. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Authors: Jerry R Mendell; Zarife Sahenk; Vinod Malik; Ana M Gomez; Kevin M Flanigan; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Eric Meadows; Sarah Lewis; Lyndsey Braun; Kim Shontz; Maria Rouhana; Kelly Reed Clark; Xiomara Q Rosales; Samiah Al-Zaidy; Alessandra Govoni; Louise R Rodino-Klapac; Mark J Hogan; Brian K Kaspar
Journal: Mol Ther Date: 2014-10-17 Impact factor: 11.454

9. Targeting protein homeostasis in sporadic inclusion body myositis.

Authors: Mhoriam Ahmed; Pedro M Machado; Adrian Miller; Charlotte Spicer; Laura Herbelin; Jianghua He; Janelle Noel; Yunxia Wang; April L McVey; Mamatha Pasnoor; Philip Gallagher; Jeffrey Statland; Ching-Hua Lu; Bernadett Kalmar; Stefen Brady; Huma Sethi; George Samandouras; Matt Parton; Janice L Holton; Anne Weston; Lucy Collinson; J Paul Taylor; Giampietro Schiavo; Michael G Hanna; Richard J Barohn; Mazen M Dimachkie; Linda Greensmith
Journal: Sci Transl Med Date: 2016-03-23 Impact factor: 17.956